OligoBlockers Blocking APP-CTFβ Toxicity at Synapses
- Coordinator
- Stichting Radboud Universiteit, Netherlands
- Runs
- 1 May 2026 to 31 October 2027
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101292724
What the project is doing
In the project's own words, from its summary on CORDIS.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia, characterized by memory loss, cognitive decline, and behavioral changes. It affects over 55 million people worldwide, with nearly 10 million new cases diagnosed each year. As global populations age, prevalence is expected to rise sharply, placing immense pressure on healthcare systems and economies. AD is a major public health challenge with no cure, and no effective treatment to stop disease progression.
Decades of research on AD have centered on amyloid-β (Aβ), yet this has proven insufficient to explain AD multifaceted cytopathology. One common denominator in the onset of AD pathology is synaptic dysfunction and network hyperexcitability. My lab recently uncovered that APP-CTFβ, the immediate precursor to Aβ, localizes at synapses where it appears to regulate excitatory function. Strikingly, over-accumulation of APP-CTFβ triggers synaptic dysfunction and network hyperexcitability.
Importantly, we found elevated levels of APP-CTFβ in post-mortem brain of AD patients. Could this be the missing piece of the puzzle? This project will develop new molecules names “OligoBlockers” targeting APP-CTFβ instead of Aβ as a novel avenue to prevent AD at an early stage.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Stichting Radboud Universiteit | Nijmegen | Netherlands | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI